Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock

Executive Vice President and Chief Legal Officer of Arcutis Biotherapeutics, Masaru Matsuda, recently sold 9,989 shares of the company's common stock on September 8, 2026, for a total of approximately $249,985. The shares were sold at prices between $25.00 and $25.12 per share, following a pre-arranged trading plan adopted on June 5, 2026, which is set to end on September 1, 2027.

Matsuda now directly owns 116,182 shares of Arcutis Biotherapeutics common stock. Despite the sale, the company's stock continues to trade at $23.38, down 19% year-to-date, but up 32% over the past year. Arcutis Biotherapeutics' market capitalization stands at $3 billion, with analysts setting price targets between $34 and $40. The recent sale comes as the company reported strong financial results for the second quarter of 2026, with net product revenue surging to $129.9 million, a 59% year-over-year increase and a 23% rise from the previous quarter.

These positive sales figures led to Arcutis Biotherapeutics achieving profitability for the first time, with Guggenheim raising its price target for the company from $35 to $38, while maintaining a Buy rating, influenced by the robust performance of key product Zoryve.